New drug targets Hard-to-Treat lung cancer mutation in major trial

NCT ID NCT07566052

Recruiting now Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 5 times

Summary

This study tests a new drug, setidegrasib, against a standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific KRAS G12D mutation. The goal is to see if setidegrasib can keep the cancer from growing longer and help people live longer. About 356 adults whose cancer worsened after prior treatments will be randomly assigned to one of the two drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Locations

Astera Cancer Care
RECRUITING

Edison, New Jersey, 08816, United States
Hokkaido University Hospital
RECRUITING

Sapporo, Hokkaido, Japan
Japanese Foundation for Cancer research
RECRUITING

Tokyo, Koto-ku, Japan
Miyagi Cancer Center
RECRUITING

Natori-shi, Miyagi, Japan
Oncura Health d.b.a.Los Angeles Cancer Network
RECRUITING

Glendale, California, 91204, United States
Virginia Cancer Specialists
RECRUITING

Arlington, Virginia, 22201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.